BioSpace News Archive

NeuroSense Therapeutics Ltd. today announced that it has enrolled and dosed the first healthy volunteer in its pharmacokinetic (PK) study (NCT05232461) of its lead combination drug candidate PrimeC developed for the treatment of amyotrophic lateral sclerosis (ALS).

Nuvectis Pharma, Inc today provided highlights from the oral presentation of NXP800 that took place yesterday at the American Association for Cancer Research (“AACR”) Conference in New Orleans.

DENTSPLY SIRONA Inc. today announced that Executive Vice President and Chief Financial Officer Jorge Gomez has resigned from the Company, effective May 6, 2022, to assume a CFO position at another public company.

NEOGEN Corporation (NASDAQ: NEOG) announced today that it has added a new product to the trusted Prozap ® insect control line.

Altamira Therapeutics Ltd. announced that the International Journal of Molecular Sciences published a peer-reviewed paper confirming the Company’s positive research findings regarding the in vitro efficacy and safety of its drug-free nasal spray, Bentrio™, against the SARS-CoV-2 Delta variant.

Predicine, a global molecular insights company, announced that it will highlight the clinical utility of its full suite of genomic profiling solutions at the 2022 AACR conference being held April 8-13, 2022, in New Orleans.

Global health services company Cigna Corporation will be hosting its Investor Day on Friday, June 3, 2022 in New York City.

Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, announced an expanded partnership with DaVita Inc., a leading kidney care provider.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), today announced study results in which opaganib (ABC294640)1, a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered into an agreement with Merck, known as MSD outside the United States and Canada.